ReviewCurrent gastroenterology reports2015
Small intestinal fungal overgrowth.
Review in Current gastroenterology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for Malabsorption.United European gastroenterology journal · 2025Guideline
- Clinical Utility and Diagnostic Yield of Duodenal Versus Jejunal Aspirates for Small Intestinal Bacterial or Fungal Overgrowth.Digestive diseases and sciences · 2026Article
- Candida Enteritis Diagnoses in the United States: Prevalence and Clinical Insights from a Large Commercial Insurance Database.Digestive diseases and sciences · 2026Article
- Clinical Significance of Intestinal Fungal Overgrowth: Integrating the Gut Mycobiome into Modern Gastroenterology.Microorganisms · 2026Review
- Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth (SIBO).JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Article
- Small intestinal microbiome, the underrated maestro of SIMO disease.FEMS microbiology reviews · 2026Review
- Small Intestinal Bacterial Overgrowth in a Healthy Female Patient Caused by Long-term Oral Proton Pump Inhibitor Administration.Internal medicine (Tokyo, Japan) · 2025Article
- Dietary Tart Cherry and Fructooligosaccharides Promote Bone Health via the Gut Microbiota and Increased Bone Formation.Nutrients · 2025Article
- Interplay of constipation, intestinal barrier dysfunction and fungal exposome in aetiopathogenesis of Parkinson's disease: hypothesis with supportive data.The Biochemical journal · 2025Article
- Gut Mycobiome: Latest Findings and Current Knowledge Regarding Its Significance in Human Health and Disease.Journal of fungi (Basel, Switzerland) · 2025Review
- Small Intestinal Bacterial and Fungal Overgrowth: Health Implications and Management Perspectives.Nutrients · 2025Review
- Standardisation of high throughput microdilution antifungal susceptibility testing for Candida albicans and Cryptococcus neoformans.Scientific reports · 2024Article
- Multiple brain abscesses in a neonate: a rare case report along with review of literature.Annals of medicine and surgery (2012) · 2024Article
- Review
- Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes.Digestive diseases and sciences · 2023Review
- Pros and Cons of Breath Testing for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth.Gastroenterology & hepatology · 2023Article
- Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO.Microorganisms · 2023Review
- Individuals with Inflammatory Bowel Disease Have an Altered Gut Microbiome Composition of Fungi and Protozoa.Microorganisms · 2022Article
- CouldJournal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. Importantly, whether eradication or its treatment leads to resolution of symptoms remains unclear; at present, a 2-3-week course of antifungal therapy is recommended and may be effective in improving symptoms, but evidence for eradication is lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.